Galapagos looking for acquisitions after drug deal
AMSTERDAM (Reuters) - Galapagos is looking for acquisitions after it received $150 million euros in upfront payments from a deal with U.S. Abbott Laboratories (ABT.N) for its leading drug.
"It would have to fit into what we are already doing and make financial sense," Chief Executive Onno van de Stolpe told a news conference on Wednesday.
(Reporting by Anthony Deutsch, writing by Ben Deighton)
WASHINGTON - U.S. small business sentiment bounced back from a seven-month low in November, with owners setting their sights on creating more jobs and expanding operations.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.